"pd-l1 on ctcs as promising prognostic biomarker in advanced nsclc" filippo g. dall'olio, md
Published 3 years ago • 72 plays • Length 7:18Download video MP4
Download video MP3
Similar videos
-
0:55
challenges associated with biomarker testing for pd-l1 in nsclc
-
4:50
nsclc: challenges with pd-l1 as biomarker
-
3:43
biomarkers in nsclc: a pathologist's insight into pd-l1 and tmb
-
2:13
the value of pd-l1 as a biomarker beyond lung cancers
-
5:36
first-line therapy in pd-l1–advanced nsclc
-
4:47
pd-l1 biomarker testing
-
1:00
dr. mason on the reliability of the pd-l1 biomarker
-
10:20
pd-l1 testing in advanced lung cancer
-
7:34
pd-l1 as a biomarker in squamous non-small cell lung cancer
-
2:24
dr. weiss on pd-l1 biomarker in lung cancer
-
1:55
dr. hirsch on value of pd-l1 testing in patients with lung cancer
-
5:47
pd-l1 testing in metastatic nsclc
-
4:15
pathologists and pd-l1
-
2:53
comparison of three different pd-l1 diagnostic tests shows a high degree of concordance
-
4:41
pd-l1 testing for nsclc
-
4:10
practical use of pd-l1 testing in stage iv nsclc
-
2:03
dr. natale on the utility of pd-l1 and tmb in lung cancer